We are a global health medtech company focused on creating cost-effective tools for consumers, including through national health programs. We are currently designing tools in workspaces for TB diagnosticians at peripheral centers and community health workers involved in active case finding, making them more powerful at their jobs. About 4000 people died of TB every day, in 2019. There were about 10 million new active TB infections in 2019 (about 27% of these cases were in India). There are 1.7 billion people who carry a dormant infection. About 10% of these will convert to active cases over their lifetimes. Each untreated active case can infect about 10-15 other people in their contact. Using state-of-the-art diagnostics (such as NAAT/PCR based ones) to over-test is simply economically not possible without continued philanthropic aid. Huge resources can only be infused into TB programs in short bursts, and are harder to sustain over decades. This model is unsustainable for high burden lower middle income countries. If people’s values, rituals and economics aren’t changing, they will continue to seek healthcare in ways and places they always have. Our strategy is to cost-effective create tools that when scaled, will be accessible to and usable by doctors at private clinics and their nearest path lab facility, not just public and private hospitals that can afford molecular testing. India, for example, is full of infrastructure that can be utilized for this purpose.